<SEC-DOCUMENT>0001564590-22-038509.txt : 20221129
<SEC-HEADER>0001564590-22-038509.hdr.sgml : 20221129
<ACCEPTANCE-DATETIME>20221129070641
ACCESSION NUMBER:		0001564590-22-038509
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20221129
DATE AS OF CHANGE:		20221129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ra Medical Systems, Inc.
		CENTRAL INDEX KEY:			0001716621
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				383661826
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38677
		FILM NUMBER:		221428302

	BUSINESS ADDRESS:	
		STREET 1:		5857 OWENS DRIVE, SUITE 300
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009
		BUSINESS PHONE:		(760) 804-1648

	MAIL ADDRESS:	
		STREET 1:		5857 OWENS DRIVE, SUITE 300
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92009
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>rmed-defa14a_20221129.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rmed-defa14a_20221129.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="border-top:Double 2.25pt;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;"><a name="filing_1"></a><a name="doc_1_1"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, DC 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.48%;margin-right:41.36%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.48%;margin-right:41.36%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">November 29, 2022</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.48%;margin-right:41.36%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ra Medical Systems, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.48%;margin-right:41.36%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Delaware</font></p></td>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">001-38677</font></p></td>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">38-3661826</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2070 Las Palmas Drive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carlsbad, California 92011</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(760) 804-1648</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report.)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:41.48%;margin-right:41.36%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:5pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96.3%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96.3%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96.3%;">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td style="width:37.43%;"></td>
<td style="width:24.98%;"></td>
<td style="width:37.49%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.0001</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RMED</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NYSE American</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company <font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01. Other Events.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Press Release</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:12.19%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 29, 2022, Ra Medical Systems, Inc (&#8220;Ra Medical&#8221; or the &#8220;Company&#8221;). and Catheter Precision, Inc. (&#8220;Catheter&#8221; or &#8220;Catheter Precision&#8221;) issued a joint press release announcing the completion of more than 20 procedures at NYU Langone Hospital utilizing Catheter&#8217;s VIVO<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> System that enables physicians to identify the origin of arrhythmias pre-procedure. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.59%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;text-transform:none;font-variant: normal;">Additional Information and Where to Find It</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 12, 2022, Ra Medical announced entering into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with privately held Catheter Precision, Inc. (&#8220;Catheter&#8221;), a medical device and technology company focused in the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger transaction (the &#8220;Merger&#8221;). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger is currently expected to close before the end of 2022, subject to satisfying certain closing conditions, including the receipt of shareholder approval by both companies. The descriptions of the Merger, the proposals to be voted on in connection with the Merger at the Ra Medical Special Meeting of Stockholders, Catheter and the other transactions and matters contemplated thereby that are referenced herein do not purport to be complete and are qualified in their entirety by reference to the Company&#8217;s Reports filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), including the Current Reports on Form 8-K filed on September 12, 2022 and September 2, 2022, the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2022 and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available on the SEC website, as well as the Company&#8217;s preliminary proxy statement relating to the Merger with Catheter Precision  that was filed with the SEC on September 23, 2022, as further described below.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication relates to the proposed Merger involving Catheter and the Company and may be deemed to be solicitation material in respect of the proposed transaction. In connection with the proposed Merger between Catheter and the Company, on September 23, 2022, the Company filed a preliminary proxy statement with the SEC and intends to file a definitive proxy statement (the &#8220;Definitive Proxy&#8221;) to call, give notice of and hold a meeting of its stockholders to vote to approve, among other matters, (a) the Merger, and (b) the issuance of the shares of the Ra Medical Common Stock to be issued pursuant to the terms of the Merger Agreement. This communication is not a substitute for the Definitive Proxy or any other documents that the Company may file with the SEC or send to the Company&#8217;s stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE DEFINITIVE AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE DOCUMENTS (WHEN THEY ARE AVAILABLE) AND OTHER RELATED DOCUMENTS FILED WITH THE SEC AT THE SEC&#8217;S WEBSITE AT WWW.SEC.GOV, ON RA MEDICAL&#8217;S INVESTOR RELATIONS WEB PAGE AT HTTPS://IR.RAMED.COM/.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter Precision also intends to furnish an information statement and consent solicitation to its stockholders in connection with the proposed Merger as part of the PPM/Joint Information Statement (as defined below). The only matters that the Company is seeking approval for at the Special Meeting of Stockholders are the matters that are set forth in the Definitive Proxy.&nbsp;&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Definitive Proxy and PPM/Joint Information Statement contain or will contain important information about Catheter Precision, the proposed Merger and related matters.&nbsp;&nbsp;In addition, on September 12, 2022, the Company&nbsp;&nbsp;filed a Current Report on Form 8-K that included certain audited financial statements of Catheter Precision for the two-year period ended December 31, 2021 (the &#8220;Catheter Audited Financial Statements&#8221;), the unaudited financial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-2</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statements of Catheter Precision for the periods ended June 30, 2022 and June 30, 2021 (the &#8220;Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the &#8220;Catheter Precision Financial Statements&#8221;), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the &#8220;Pro Forma Financial Information,&#8221; and collectively with the Catheter Precision Financial Statements, the &#8220;Financial Information&#8221;).</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ra Medical intends to mail the Definitive Proxy to Ra Medical stockholders, and Catheter Precision intends to electronically disseminate the PPM/Joint Information Statement. <font style="font-style:italic;">INVESTORS AND SECURITYHOLDERS OF RA MEDICAL AND CATHETER PRECISION ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RA MEDICAL, CATHETER PRECISION AND THE PROPOSED MERGER.&#160;</font>THIS COMMUNICATION IS NOT A SUBSTITUTE FOR THE PPM/JOINT INFORMATION STATEMENT, THE DEFINITIVE PROXY, THE CURRENT REPORTS ON FORM 8-K, INCLUDING THE CURRENT REPORT ON FORM 8-K FILED ON SEPTEMBER 12, 2022, THE COMPANY&#8217;S QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2022, OR ANY OTHER DOCUMENTS THAT RA MEDICAL AND/OR CATHETER PRECISION MAY FILE WITH THE SEC OR SEND TO THEIR RESPECTIVE SECURITYHOLDERS IN CONNECTION WITH THE PROPOSED TRANSACTIONS. INVESTORS AND SECURITYHOLDERS MAY OBTAIN FREE COPIES OF RA MEDICAL&#8217;S DOCUMENTS FILED WITH THE SEC, ONCE AVAILABLE, ON THE RA MEDICAL WEBSITE OR ON THE SEC&#8217;S WEBSITE.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited pro forma combined financial information does not purport to represent the actual results of operations that the Company and Catheter Precision would have achieved had the companies been combined during the periods presented in the unaudited pro forma combined financial statements and is not intended to project the future results of operations that the combined company may achieve after the Merger. The unaudited pro forma combined financial information does not reflect any potential cost savings that may be realized as a result of the Merger and also does not reflect any restructuring or integration-related costs to achieve those potential cost savings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No Offer or Solicitation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of Common Stock being issued in the Merger (the &#8220;Securities&#8221;) are being offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof. Catheter Precision and Ra Medical intend to distribute a Private Placement Memorandum/Joint Information Statement (the &#8220;PPM/Joint Information Statement&#8221;) to the stockholders of Catheter Precision, and Catheter Precision stockholders are encouraged to carefully read the PPM/Joint Information Statement, together with Ra Medical&#8217;s SEC filings, which will contain important information concerning the transaction.&nbsp;&nbsp; </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Securities have not been registered under the Securities Act and such Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participants in the Solicitation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter, the Company, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed transaction. Information about the Company&#8217;s directors and executive officers is set forth in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 which was filed with the SEC on March 24, 2022, the Company&#8217;s definitive proxy statement for its annual meeting of stockholders filed on April 21, 2022, and in subsequent filings made by the Company with the SEC. OTHER INFORMATION REGARDING THE INTERESTS OF SUCH INDIVIDUALS, AS WELL AS INFORMATION REGARDING CATHETER&#8217;S DIRECTORS AND EXECUTIVE OFFICERS AND OTHER PERSONS WHO MAY BE DEEMED PARTICIPANTS IN THE PROPOSED TRANSACTION, WILL BE </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-3</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SET FORTH IN THE DEFINITIVE PROXY AND OTHER RELEVANT MATERIALS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE. YOU MAY OBTAIN FREE COPIES OF THESE DOCUMENTS </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AT THE SEC&#8217;S WEBSITE AT WWW.SEC.GOV, ON R</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A MEDICAL&#8217;S INVESTOR RELATIONS WEB PAGE AT </font><font style="text-decoration:underline;color:#0000FF;">HTTPS://IR.RAMED.COM/</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger, future access to capital markets, and the plans and expectations of the combined company regarding Catheter&#8217;s products, including its plans, strategies, projected timelines and estimated markets, for and/or related to VIVO and the Amigo and vessel closure devices described in the exhibits hereto. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company&#8217;s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger and the ability of the Company to timely and successfully achieve the anticipated benefits of the Merger, including the ability of the combined company to access the capital markets at such times and in such amounts, and on such terms, as needed to meet the Net Cash requirements of the Merger Agreement, execute its future business strategies and maintain its listing on the NYSE American or other national stock exchange, potential application of SEC and/or exchange &#8220;shell company&#8221; rules, and the ability of the combined company to successfully pursue its product lines in the manner and in the timeframe described here. The Merger Agreement contains certain closing conditions, including a minimum prevailing stock price for Ra Medical and Net Cash amount at closing, which do not constitute representations or covenants of either party, and are subject to waiver by the parties.&nbsp;&nbsp;If Ra Medical&#8217;s stock price drops below certain levels, the amount of merger consideration, if any, received by Catheter stockholders will be adversely impacted. The parties have reserved the right to waive conditions to the closing of the Merger, including the stock price condition, and revise the Merger Agreement. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#8220;Risk Factors&#8221; and elsewhere in the Company&#8217;s most recent filings with the SEC, including the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, Exhibits 99.7 and 99.8 attached to the Company&#8217;s Preliminary Proxy Statement filed on September 23, 2022, as amended on November 4, 2022, Current Report on Form 8-K filed on September 12, 2022, and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov.&nbsp;&nbsp;Important business and financial information about Catheter&#8217;s business and the related discussion and analysis of financial condition and results of operations of Catheter are described in &#8220;Catheter Precision Summary Business Description,&#8221; included as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022, and &#8220;Catheter Precision Management&#8217;s Discussion and Analysis,&#8221; included as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022, and in the Company&#8217;s Preliminary Proxy Statement filed on September 23, 2022, as amended on November 4, 2022.&nbsp;&nbsp;This information should be read in conjunction with certain audited financial statements of Catheter for the two-year period ended December 31, 2021 (the &#8220;Catheter Precision Audited Financial Statements&#8221;), the unaudited financial statements of Catheter for the periods ended June 30, 2022 and June 30, 2021 (the &#8220;Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the &#8220;Catheter Precision Financial Statements&#8221;), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the &#8220;Pro Forma Financial Information,&#8221; and collectively with the Catheter Financial Statements, the &#8220;Financial Information&#8221;), which were filed as Exhibit 99.4, Exhibit 99.5, and Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022, respectively. Risks and uncertainties related to the Merger, Catheter, and the projections and estimates described in the exhibits hereto that may cause actual results to differ materially from those expressed or implied in any forward-looking statement are described in &#8220;Risk Factors -- Risks Related to the Merger with Catheter Precision and &#8211; Risks Related to Our Evaluation of Strategic Alternatives for our Legacy Assets,&#8221; and &#8220;Risk Factors &#8211; Risks Related to the Business of Catheter Precision,&#8221; which were filed as Exhibit 99.7 and Exhibit 99.8 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022, respectively, and in the Company&#8217;s Preliminary Proxy Statement filed on September 23, 2022, as amended on November 4, 2022. These documents can be accessed on the Company&#8217;s Investor Relations page at https://ir.ramed.com/ by clicking on the link titled &#8220;SEC Filings.&#8221; The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, and ongoing volatility </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-4</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the stock markets and the U.S. economy in general. The extent to which the COVID-19 pandemic impacts the Company&#8217;s and Catheter&#8217;s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements included in this communication are made only as of the date hereof. The Company and Catheter assume no obligation and do not intend to update these forward-looking statements, except as required by law.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk529457282"></a><a name="_Hlk529457282"></a>(d) Exhibits</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Joint Press Release of Ra Medical Systems, Inc. and Catheter Precision, Inc. on November 29, 2022.</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL).</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RA MEDICAL SYSTEMS, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 29, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jonathan Will McGuire</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jonathan Will McGuire</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(Principal Executive Officer)</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-6</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.19%;">
<tr>
<td style="width:48.1%;"></td>
<td style="width:48.1%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcdw3eiiwqbh000001.jpg" title="" alt="" style="width:175px;height:37px;"></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gcdw3eiiwqbh000002.jpg" title="" alt="" style="width:172px;height:61px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Catheter Precision&#8217;s VIVO&#8482; Systems Used in More Than 20 Procedures at NYU Langone Hospital</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">MT. OLIVE, N.J. and CARLSBAD, Calif. (November 29, 2022)<font style="font-weight:normal;"> &#8211; </font><font style="font-size:10pt;font-weight:normal;">Catheter Precision, Inc.</font><font style="font-weight:normal;">, a medical device and technology company focused on cardiac electrophysiology, announces the completion of more than&nbsp;&nbsp;20 procedures at NYU Langone Hospital utilizing the VIVO System</font><font style="Background-color:#FFFFFF;color:#393939;font-size:13.5pt;font-family:Montserrat;font-weight:normal;"> </font><font style="font-weight:normal;">that enables physicians to identify the origin of arrhythmias pre-procedure. On September 12, 2022 privately held Catheter Precision announced a </font><font style="font-size:10pt;font-weight:normal;">definitive merger agreement</font><font style="font-weight:normal;"> with Ra Medical Systems (NYSE American: RMED), which, if completed, will result in a combined publicly traded company focusing on the cardiac electrophysiology market. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Completing the first 20 cases with VIVO at NYU Langone hospital is another milestone demonstrating clinical acceptance of our VIVO system,&#8221; said David Jenkins, Catheter Precision CEO. &#8220;Continued commercial usage indicates that the physicians believe VIVO provides benefit and we look forward to continuing to draw on their expertise for future growth including product development.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Identifying the origins of ventricular arrhythmias can be difficult and time consuming,&#8221; said Larry Chinitz, Director of electrophysiology and the Heart Rhythm Center at NYU Langone. &#8220;VIVO has enabled us to rapidly identify the targeted ablation area and provide additional insight into the patient&#8217;s unique anatomy and arrythmia more rapidly. In addition to saving procedural time, combining all of this data in advance of the procedure has potential benefits for better treatment outcomes.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter Precision&#8217;s lead product, VIVO&#8482; (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has been awarded the CE mark. The company also intends to pursue a second generation of Amigo&#174;, a previously FDA-cleared and CE mark robotic arm that can be used to remotely control catheters outside of the procedure room. Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the definitive merger agreement with Ra Medical Systems, Catheter Precision will become a wholly owned subsidiary of Ra Medical Systems in a stock-for-stock reverse merger transaction. The merger is expected to close in the fourth quarter of 2022 or the first quarter of 2023, subject to satisfying certain closing conditions, including the receipt of required shareholder approval.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Catheter Precision</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Additional Information and Where to Find It</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 12, 2022, Ra Medical announced entering into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with privately held Catheter Precision, Inc. (&#8220;Catheter&#8221;), a medical device and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology company focused </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger transaction (the &#8220;Merger&#8221;). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger is currently expected to close before the end of 2022 or during the first quarter of 2023, subject to satisfying certain closing conditions, including the receipt of shareholder approval by both companies. The descriptions of the Merger, the proposals to be voted on in connection with the Merger at the Ra Medical Special Meeting of Stockholders, Catheter and the other transactions and matters contemplated thereby that are referenced herein do not purport to be complete and are qualified in their entirety by reference to the Company&#8217;s Reports filed with the Securities and Exchange Commission (&#8220;SEC&#8221;), including the Current Reports on Form 8-K filed on September 12, 2022 and September 2, 2022, the Company&#8217;s Quarterly Report on Form 10-Q for the period ended September 30, 2022 and any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available on the SEC website, as well as the Company&#8217;s preliminary proxy statement relating to the Merger with Catheter Precision that was filed with the SEC on September 23, 2022, as amended on November 4, 2022, as further described below.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication relates to the proposed Merger involving Catheter and the Company and may be deemed to be solicitation material in respect of the proposed transaction. In connection with the proposed Merger between Catheter and the Company, on September 23, 2022, the Company filed a preliminary proxy statement with the SEC, as amended on November 4, 2022, and intends to file a definitive proxy statement (the &#8220;Definitive Proxy&#8221;) to call, give notice of and hold a meeting of its stockholders to vote to approve, among other matters, (a) the Merger, and (b) the issuance of the shares of the Ra Medical Common Stock to be issued pursuant to the terms of the Merger Agreement. This communication is not a substitute for the Definitive Proxy or any other documents that the Company may file with the SEC or send to the Company&#8217;s stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. INVESTORS AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE DOCUMENTS (WHEN THEY ARE AVAILABLE) AND OTHER RELATED DOCUMENTS FILED WITH THE SEC AT THE SEC&#8217;S WEBSITE AT WWW.SEC.GOV&nbsp;&nbsp;,AND ON RA MEDICAL&#8217;S INVESTOR RELATIONS WEB PAGE AT HTTPS://IR.RAMED.COM/.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter Precision also intends to furnish an information statement and consent solicitation to its stockholders in connection with the proposed Merger as part of the PPM/Joint Information Statement (as defined below). The only matters that the Company is seeking approval for at the Special Meeting of Stockholders are the matters that are set forth in the Definitive Proxy.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Definitive Proxy and PPM/Joint Information Statement will contain important information about Catheter Precision, the proposed Merger and related matters.&nbsp;&nbsp;In addition, on September 12, 2022, the Company&nbsp;&nbsp;filed a Current Report on Form 8-K that included certain audited financial statements of Catheter Precision for the two-year period ended December 31, 2021 (the &#8220;Catheter Audited Financial Statements&#8221;), the unaudited financial statements of Catheter Precision for the periods ended June 30, 2022 and June 30, 2021 (the &#8220;Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the &#8220;Catheter Precision Financial Statements&#8221;), and the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-8</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the &#8220;Pro Forma Financial Information,&#8221; and collectively with the Catheter Precision Financial Statements, the &#8220;Financial Information&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ra Medical intends to mail the Definitive Proxy to Ra Medical stockholders, and Catheter Precision intends to electronically disseminate the PPM/Joint Information Statement. INVESTORS AND SECURITYHOLDERS OF RA MEDICAL AND CATHETER PRECISION ARE URGED TO READ THESE MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT RA MEDICAL, CATHETER PRECISION AND THE PROPOSED MERGER. THIS COMMUNICATION IS NOT A SUBSTITUTE FOR THE PPM/JOINT INFORMATION STATEMENT, THE DEFINITIVE PROXY, THE CURRENT REPORTS ON FORM 8-K, INCLUDING THE CURRENT REPORT ON FORM 8-K FILED ON SEPTEMBER 12, 2022, THE COMPANY&#8217;S QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2022, OR ANY OTHER DOCUMENTS THAT RA MEDICAL AND/OR CATHETER PRECISION MAY FILE WITH THE SEC OR SEND TO THEIR RESPECTIVE SECURITYHOLDERS IN CONNECTION WITH THE PROPOSED TRANSACTIONS. INVESTORS AND SECURITYHOLDERS MAY OBTAIN FREE COPIES OF RA MEDICAL&#8217;S DOCUMENTS FILED WITH THE SEC, ONCE AVAILABLE, ON THE RA MEDICAL WEBSITE OR ON THE SEC&#8217;S WEBSITE.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited pro forma combined financial information does not purport to represent the actual results of operations that the Company and Catheter Precision would have achieved had the companies been combined during the periods presented in the unaudited pro forma combined financial statements and is not intended to project the future results of operations that the combined company may achieve after the Merger. The unaudited pro forma combined financial information does not reflect any potential cost savings that may be realized as a result of the Merger and also does not reflect any restructuring or integration-related costs to achieve those potential cost savings.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">No Offer or Solicitation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of Common Stock being issued in the Merger (the &#8220;Securities&#8221;) are being offered and sold in transactions exempt from registration under the Securities Act, in reliance on Section 4(a)(2) thereof. Catheter Precision and Ra Medical intend to distribute a Private Placement Memorandum/Joint Information Statement (the &#8220;PPM/Joint Information Statement&#8221;) to the stockholders of Catheter Precision, and Catheter Precision stockholders are encouraged to carefully read the PPM/Joint Information Statement, together with Ra Medical&#8217;s SEC filings, which will contain important information concerning the transaction.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Securities have not been registered under the Securities Act and such Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Participants in the Solicitation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-9</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catheter, the Company, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of the Company in connection with the proposed transaction. Information about the Company&#8217;s directors and executive officers is set forth in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 which was filed with the SEC on March 24, 2022, the Company&#8217;s definitive proxy statement for its annual meeting of stockholders filed on April 21, 2022, and in subsequent filings made by the Company with the SEC. OTHER INFORMATION REGARDING THE INTERESTS OF SUCH INDIVIDUALS, AS WELL AS INFORMATION REGARDING CATHETER&#8217;S DIRECTORS AND EXECUTIVE OFFICERS AND OTHER PERSONS WHO MAY BE DEEMED PARTICIPANTS IN THE PROPOSED TRANSACTION, WILL BE SET FORTH IN THE DEFINITIVE PROXY AND OTHER RELEVANT MATERIALS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE. YOU MAY OBTAIN FREE COPIES OF THESE DOCUMENTS AT THE SEC&#8217;S WEBSITE AT WWW.SEC.GOV&nbsp;&nbsp;,AND ON RA MEDICAL&#8217;S INVESTOR RELATIONS WEB PAGE AT HTTPS://IR.RAMED.COM/.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This communication contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion and effects of the proposed Merger, future access to capital markets, and the plans and expectations of the combined company regarding Catheter&#8217;s products, including its plans, strategies, projected timelines and estimated markets, for and/or related to VIVO and the Amigo and vessel closure devices described above. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company&#8217;s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed Merger, satisfaction of closing conditions precedent to the consummation of the proposed Merger, potential delays in consummating the Merger and the ability of the Company to timely and successfully achieve the anticipated benefits of the Merger, including the ability of the combined company to access the capital markets at such times and in such amounts, and on such terms, as needed to meet the Net Cash requirements of the Merger Agreement, execute its future business strategies and maintain its listing on the NYSE American or other national stock exchange, potential application of SEC and/or exchange &#8220;shell company&#8221; rules, and the ability of the combined company to successfully pursue its product lines in the manner and in the timeframe described here. The Merger Agreement contains certain closing conditions, including a minimum prevailing stock price for Ra Medical and Net Cash amount at closing, which do not constitute representations or covenants of either party, and are subject to waiver by the parties.&nbsp;&nbsp;If Ra Medical&#8217;s stock price drops below certain levels, the amount of merger consideration, if any, received by Catheter stockholders will be adversely impacted. The parties have reserved the right to waive conditions to the closing of the Merger, including the stock price condition, and revise the Merger Agreement. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#8220;Risk Factors&#8221; and elsewhere in the Company&#8217;s most recent filings with the SEC, including the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, Exhibits 99.7 and 99.8 attached the Company&#8217;s Preliminary Proxy Statement filed on September 22, 2022, as amended on November 4, 2022, Current Report on Form 8-K filed on September 12, 2022, any prior or subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at <font style="font-size:10pt;">www.sec.gov</font>, and in the Definitive Proxy, when filed.&nbsp;&nbsp;Important business and financial information about Catheter&#8217;s business and the related discussion and analysis of financial condition and results of operations of Catheter are described in &#8220;Catheter Precision Summary Business Description,&#8221; included as Exhibit 99.2 to the Company&#8217;s Current </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-10</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Report on Form 8-K filed on September 12, 2022, and &#8220;Catheter Precision Management&#8217;s Discussion and Analysis,&#8221; included as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and in </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s Preliminary Proxy Statement filed on September 22, 2022, </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as amended on November 4, 2022</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;This information should be read in conjunction with certain audited financial statements of Catheter for the two-year period ended December 31, 2021 (the &#8220;Catheter Precision Audited Financial Statements&#8221;), the unaudited financial statements of Catheter for the periods ended June 30, 2022 and June 30, 2021 (the &#8220;Catheter Precision Unaudited Financial Statements and together with the Catheter Precision Audited Financial Statements, the &#8220;Catheter Precision Financial Statements&#8221;), and the unaudited pro forma combined financial information of the combined company as of June 30, 2022 and for the year ended December 31, 2021 and the six months ended June 30, 2022 (the &#8220;Pro Forma Financial Information,&#8221; and collectively with the Catheter Financial Statements, the &#8220;Financial Information&#8221;), which were filed as Exhibit 99.4, Exhibit 99.5, and Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022, respectively. Risks and uncertainties related to the Merger, Catheter, and the projections and estimates described above that may cause actual</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results to differ materially from those expressed or implied in any forward-looking statement are described in &#8220;Risk Factors -- Risks Related to the Merger with Catheter Precision and &#8211; Risks Related to Our Evaluation of Strategic Alternatives for our Legacy Assets,&#8221; and &#8220;Risk Factors &#8211; Risks Related to the Business of Catheter Precision,&#8221; which were filed as Exhibit 99.7 and Exhibit 99.8 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2022, respectively</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company&#8217;s Preliminary Proxy Statement filed on September 22, 2022, </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as amended on November 4, 2022</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. These documents can be accessed on the Company&#8217;s Investor Relations page at https://ir.ramed.com/ by clicking on the link titled &#8220;SEC Filings.&#8221; The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, and ongoing volatility in the stock markets and the U.S. economy in general. The extent to which the COVID-19 pandemic impacts the Company&#8217;s and Catheter&#8217;s businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The forward-looking statements included in this communication are made only as of the date hereof. The Company and Catheter assume no obligation and do not intend to update these forward-looking statements, except as required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">CONTACTS:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">For Catheter Precision</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Missiaen Huck</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">973-691-2000</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mhuck@catheterprecision.com</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">For Ra Medical Systems</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#222222;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">LHA Investor Relations</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#222222;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Jody Cain</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#222222;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">310-691-7100</font><br /><font style="Background-color:#FFFFFF;">jcain@lhai.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#&nbsp;&nbsp; #&nbsp;&nbsp; #</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-11</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>gcdw3eiiwqbh000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcdw3eiiwqbh000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z 1(# 2(  A$! Q$!_\0
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M;^XDU"[#/</A5G8!0&(  !X  %4/[2U#_H(WG_@2_P#C3;[_ )"-W_UWD_\
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MH)K@/BCXFU;3[O2M#T><VLVH-\UP#A@-P4 'MR>3UXKN=!_Y%W3/^O2+_P!
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M,I_$475U;V5N]Q=3QP0H,M)(P51^)KROX:QG2/B%XFT*UD<:?"6,<3-G!#@
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M'#?!R"YE77]6D@:*WOKE6A+?Q8+DX]0-P&:A^,G_ "$?"_\ U\M_-*]6551
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M7$_V7I__ #X6O_?E?\*TH8:]-24FKDSJVE:QT?BVU^&@\,WK6#:<+X1G[/\
M99,N7[< ]/7-;7@Y[E_@O*;DN?\ 1+@1%_\ GGAMN/;TKEO#VCZ7+KELDFFV
M;J6Y5H%(_E7L=]%&-(N81&GE>0R[-HVXVGC'I2Q"]G%0O?6^HZ;YFY'$_!G_
M )$!?^OJ7^8KG/#.LV7A7XG^)HM;E^QBZD)BDD!"GYBPY]"#P>E=G\+XHXO
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5-8VQ)MHR28EY^4>U%>LZFIR*)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gcdw3eiiwqbh000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gcdw3eiiwqbh000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #1 DP# 2(  A$! Q$!_\0
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MJLH _*J2NKDRE9I&U1114E!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M)0 M%)3=QP3TH ?12#I10 M(:6FMUH 7-+6*-1-OXB:PF)VRQ[XB>Y[BM<9Q
MSP:;C9DQDG>W0=124'-3<HCGD\N&1ST52:Y;P)*9K2\D;EFG8G\ZU_$EP+?P
M]>ONVGRR ?>L/X;'?X>+G[Q?D^M=,8?N',XIU+XB,/F=I12&BN<[+BT4A.!F
MH4E5Y6CW?.HR0/2@+J]B>BF]J6@8M%%% !1110 4444 %%%% !1110 4444
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MSK0[1:***8!12$TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH *,BD/7-)COZ]J %R/6ES3<#'2DR/7Z4 /HI,@^]&#VH 6BDI:
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M'+(%M+QD4D!MG6O0_"WB.V\5:'#JEK&Z12] XYKXY<_NSPPP#VXKZC^#N?\
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MEO6/B9XSMM;OH(-8"10RLJCR\\9KV[X5:SJ.O^"X;[5+CS[AV.6QBOF?7_\
MD8]4_P"NS_S-?17P2_Y)U:_[QH V_%3ZQ;W=B=.U5;6.>0(RM"'_ !S6/<>*
MM3TZ;5X+R19/+0QV;JF"TN.N/:NZN;*"[:(S)N,3;D]C5*;0=-EE\Z:W#.'+
MY/3)ZT 1^%IK^X\.64NJ2++>NG[UU& 36N"JC -16\$=K"(HAM0=%]*FY]*
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MUV11K_=9!^HK[9T\9TNS';R$_P#017Q*S;H8V]60_J*^VM-_Y!=G_P!<$_\
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MKZV^'%R]U\/]'FE.6:#^1-?)=TJ6TUQ GS+'(T>?7!Q7UA\+^?AOHN?^>/\
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M@6X'4&D$L6=OF)]-PH \I/P!\.M@"YG W9(KU'3[,:=80VB.62% BDCL*L#
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MW/I8.9+:X.2?QKT96#$E2,5Q_A+XDZ#XND^SVTKVMZ!S:7 VO78(<D\#CI0
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MU.\-Q;6=W(WV6$L0IBQQQ7TBO KQCQ';0V'QX\(6MM&L<$5ML1%'"@9KVF@
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M[;!N,,9?[^T9^M<)X9^%>D>'M1_M2>6?4=2/_+:X?=CZ5WJY!P3R: '4444
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M[6M,36M%O-.D.Q;F(QEOK5+PAX;C\)^&[;1XIC*D&<.>^: -ZBDQ2T %>?\
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M4 %%%% !1110 4AZT44 +2?Q444 ,'WJ=_'^%%% #J*** $;[M,/^N'THHH
MDHHHH *1ONT44 (OW!2]Z** $3[OXTZBB@ HHHH :W4?6D3[OXFBB@!]%%%
M#6Z4IZBBB@!32-]T_2BB@"+_ )9GZ"I5^Z/I110 M1CHWUHHH D'2BBB@"!O
M]=^-3T44 (>AIB_ZL?6BB@!%^Z?K4A[444 ,_P"6IIPZM110 ZBBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
